Active Filter(s):
Details:
Recently published results from a Phase 1 trial conducted by ONCOtherapeutics among 28 heavily previously treated MM patients administered RUX, lenalidomide (LEN) and MP demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids.
Lead Product(s): Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
The marketing authorisation application was based on data from the BLISS-LN study, which showed that, belimumab added to standard therapy increased renal response rates and helped to prevent worsening of kidney disease in patients with active lupus nephritis.
Lead Product(s): Belimumab,Methylprednisolone,Cyclophosphamide
Therapeutic Area: Immunology Product Name: Benlysta
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 22, 2021
Details:
Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered Ruxolitinib, lenalidomide and methylprednisolone demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids.
Lead Product(s): Ruxolitinib Phosphate,Lenalidomide,Methylprednisolone
Therapeutic Area: Oncology Product Name: Jakafi
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 15, 2020
Details:
PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Lead Product(s): PR006,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR006
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for nGD in 2021.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2020
Details:
The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The drug delivery technology releases an anti-inflammatory molecule (methylprednisolone) and can create a favorable micro-environment to promote tissue repair and recovery after neurological injury.
Lead Product(s): Methylprednisolone
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
GRAVITAS-301 results show that treatment with itacitinib-corticosteroids combo did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids.
Lead Product(s): Itacitinib,Prednisone,Methylprednisolone
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020